Clinical Trial Update: Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cetuximab and vemurafenib in combination with FOLFIRI for BRAF V600E mutated advanced colorectal cancer is being reported as an updat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN